Stopping Pharma’s Ripoffs and Drug Savings For All Act
- Bill Number
- H.R. 890
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Commerce
- Status
- Introduced
- Latest Action
- 2025-01-31: Referred to the House Committee on the Judiciary.
- Last Updated
- 2025-06-09T14:17:10Z
AI-Generated Summary
Purpose of the Legislation
The "Stopping Pharma's Ripoffs and Drug Savings For All Act" (H.R. 890) aims to prevent the improper extension of patent exclusivity for drugs and biological products (biologics) through practices like "double patenting," where multiple patents on the same invention unnecessarily delay generic competition. This is intended to promote faster market entry for lower-cost alternatives, ultimately reducing drug prices for consumers.
Key Provisions
- Presumption of Patent Term Disclaimer:
- In legal challenges to the validity of patents related to drugs (under FDA approval processes) or biologics (under public health laws), or in specific patent infringement suits involving generics, the patent holder is presumed to have given up (disclaimed) the remaining term of later patents once the first related patent expires.
- This presumption applies unless the patent holder proves, by a majority of evidence (preponderance standard), that the later patents cover "patentably distinct" inventions—meaning inventions that are meaningfully different and not obvious variations of the original.
- If distinct inventions are proven, the full patent terms, including any extensions granted by the U.S. Patent and Trademark Office (USPTO), remain in effect unless the holder explicitly disclaims them in writing.
- USPTO Review and Reporting:
- The USPTO Director must review current patent examination processes to assess if they adequately prevent issuing non-distinct patents for the same drug or biologic.
- The review evaluates whether new guidelines or procedures are needed to improve examinations and reduce patents that improperly extend exclusivity.
- Within one year of enactment, the Director must report findings and recommendations to the House Judiciary Committee.
Significant Changes to Existing Law
- Amends Section 253 of Title 35, U.S. Code (which deals with patent disclaimers and dedications), by adding a new subsection (c) specifically targeting drug and biologic patents.
- Introduces a new presumption of term disclaimer in pharma-related patent challenges, shifting the burden to patent holders to justify extended terms—unlike current law, which does not automatically presume disclaimers for such patents.
- Mandates a proactive USPTO review of examination practices, which could lead to updated guidelines but does not immediately change approval processes.
Potential Impacts
- On Government Agencies: The USPTO will face increased workload for the required review and potential new procedures, possibly improving patent quality in the pharmaceutical sector. The FDA and courts handling drug approvals or challenges may see more streamlined patent disputes.
- On Citizens: Could accelerate generic drug and biosimilar availability, lowering prescription costs and improving access to affordable medications, especially for chronic conditions.
- On International Relations: Minimal direct impact, though it may influence global pharmaceutical trade by making U.S. patents less extendable, potentially pressuring foreign companies to adapt strategies for the U.S. market.
Main Stakeholders Affected
- Pharmaceutical and Biotech Companies: Patent holders (innovators) may find it harder to maintain long exclusivity periods, reducing revenue from branded drugs but encouraging innovation in truly distinct products.
- Generic and Biosimilar Manufacturers: Benefit from presumed shorter patent terms, enabling earlier market entry and competition.
- Consumers and Patients: Primary beneficiaries through potential drug price reductions.
- USPTO and Judiciary: USPTO must implement reviews and possible changes; courts will apply the new presumption in relevant cases.
- Congress and Policymakers: The House Judiciary Committee receives the report, informing future oversight on drug pricing and patent reform.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens anti-"evergreening" measures (filing minor variations to extend patents) in patent law, potentially increasing successful challenges to pharma patents without altering core constitutional protections for inventors under Article I, Section 8 (promoting science and useful arts). The preponderance standard is a common evidentiary threshold, ensuring fairness in disputes.
- Constitutional: Aligns with the patent clause by balancing incentives for innovation against public access to inventions, avoiding undue monopolies.
- Political: Targets high drug prices as a public concern, reflecting bipartisan interest in affordability; the short title emphasizes anti-pharma sentiment, which could influence debates on broader healthcare policy but risks industry pushback on innovation incentives.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-01-31: Referred to the House Committee on the Judiciary.
- 2025-01-31: Introduced in House
- 2025-01-31: Introduced in House
Bill Versions
- Stopping Pharma’s Ripoffs and Drug Savings For All Act — issued 2025-01-31 — PDF (4 pages)